- Apotex Corp. has entered a sterile filling partnership with Halo Pharmaceuticals, securing access to injectable manufacturing capacity at Halo’s New Jersey facility.
- The agreement supports Apotex’s U.S.-focused manufacturing strategy and expands its sterile injectable production capabilities.
Apotex Corp. has announced a strategic sterile filling partnership with Halo Pharmaceuticals, securing access to a portion of the sterile injectable manufacturing capacity at Halo’s facility in Whippany, New Jersey. The agreement is intended to strengthen Apotex’s contract manufacturing network and support its U.S.-based production strategy.
The partnership provides Apotex with near-term access to sterile filling capacity, offering an alternative to developing a new facility. The company stated that this approach allows for increased operational flexibility while expanding its sterile injectable manufacturing capabilities.
Halo Pharmaceuticals operates as a CDMO providing development and manufacturing services across multiple dosage forms, including sterile injectables. Through the agreement, Apotex will gain access to vial and pre-filled syringe filling capacity while contributing its experience in sterile processing, regulatory readiness, and commercialization.
The Whippany facility is currently undergoing installation and qualification, with future regulatory inspection expected as part of its development. Apotex’s involvement will support technical and operational readiness activities, with regulatory approvals subject to U.S. Food and Drug Administration review.
“We believe this partnership enhances flexibility within our sterile injectables network while supporting efficient capacity utilization. It’s also a strong signal of our commitment to the sterile injectables market.”
Christine Baeder, President of Apotex U.S. and LATAM
